Market Closed - Nasdaq 04:00:00 2024-04-17 pm EDT 5-day change 1st Jan Change
67.2 USD -0.21% Intraday chart for Axonics, Inc. -0.74% +7.99%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Boston Scientific, Axonics Receive FTC Second Request on Merger Deal MT
Boston Scientific, Axonics Merger Prompts FTC to Request Additional Information DJ
FTC seeks additional information for Boston Scientific's $3.7 bln Axonics deal RE
Axonics Wins Shareholder Approval of Merger With Boston Scientific MT
Axonics to File for Review After Patent Board Invalidates Claims in Medtronic Case MT
Medtronic to Ask Court to Resume Patent Infringement Case Against Axonics After Favorable Patent Office Ruling MT
Axonics to Sell Rechargeable Sacral Neuromodulation System in Europe Starting April MT
North American Morning Briefing : Stock Futures -2- DJ
Axonics Q4 Earnings, Revenue Rise -- Shares Edge Higher After Hours MT
Axonics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Earnings Flash (AXNX) AXONICS Posts Q4 Revenue $109.7M MT
Boston Scientific Prices $2.17 Billion Euro-Denominated Notes Offering MT
Axonics Insider Sold Shares Worth $2,381,662, According to a Recent SEC Filing MT
Axonics Insider Sold Shares Worth $1,125,432, According to a Recent SEC Filing MT
North American Morning Briefing : TSMC Results -2- DJ
Needham Downgrades Axonics to Hold From Buy MT
North American Morning Briefing : Central Bankers -2- DJ
North American Morning Briefing : Stock Futures -2- DJ
Truist Securities Downgrades Axonics to Hold From Buy, Adjusts Price Target to $71 From $73 MT
CL King Downgrades Axonics to Neutral From Buy MT
Leerink Partners Downgrades Axonics to Market Perform From Outperform, Sets Price Target at $71 MT
Piper Sandler Downgrades Axonics to Neutral From Overweight, Cuts Price Target to $71 From $75 MT
Axonics Insider Sold Shares Worth $1,103,961, According to a Recent SEC Filing MT
North American Morning Briefing : Focus Fixed on -2- DJ
Wells Fargo Downgrades Axonics to Equalweight From Overweight, Raises Price Target to $71 From $68 MT
Chart Axonics, Inc.
More charts
Axonics, Inc. is a medical technology company, which develops and commercializes products to treat adults with bladder and bowel dysfunction. The Company has designed and developed both rechargeable (R20) and recharge-free (F15) implantable sacral neuromodulation (SNM) systems, which deliver mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of overactive bladder (OAB), urinary retention (UR) and fecal incontinence (FI). The recharge-free implantable neurostimulator (INS) is approximately 10cc in volume, utilizes constant current stimulation, an easy-to-use, intuitive recharge-free patient remote control and other related accessories. It engineered its recharge-free sacral neuromodulation (SNM) system to deliver constant-current stimulation. Its SNM system includes an easy-to-use wireless patient remote control that does not require recharging or replacement batteries.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
13
Last Close Price
67.2 USD
Average target price
71.8 USD
Spread / Average Target
+6.85%
Consensus
  1. Stock Market
  2. Equities
  3. AXNX Stock
  4. News Axonics, Inc.
  5. Axonics : Kicks Off $150 Million Common Stock Offering